GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint
29 Outubro 2024 - 7:30AM
Business Wire
GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage
biotechnology company discovering and developing glycobiology-based
therapies for cancers and inflammatory diseases, today announced
the Phase 2 analysis of the adaptive Phase 2/3 study of uproleselan
being conducted by the National Cancer Institute (NCI) and the
Alliance for Clinical Trials in Oncology in adults with newly
diagnosed acute myeloid leukemia (AML) who are 60 years or older
and fit for intensive chemotherapy. This study did not show a
statistically significant improvement in event free survival (EFS)
for patients receiving uproleselan in combination with 7+3
chemotherapy versus chemotherapy alone.
GlycoMimetics is coordinating with the Alliance for transfer of
full trial data for additional analysis, including subgroup
analysis to evaluate if there are efficacy signals in any patient
population that may merit further study in future clinical trials.
Top-line results from NCI/Alliance trial are expected to be
presented by the NCI at a future medical conference.
About GlycoMimetics, Inc.
GlycoMimetics is a late clinical-stage biotechnology company
discovering and developing glycobiology-based therapies for
cancers, including AML, and for inflammatory diseases. The
company’s scientific approach is based on an understanding of the
role that carbohydrates play in cell recognition. Its specialized
chemistry platform can be used to discover small molecule drugs,
known as glycomimetics, that alter carbohydrate-mediated
recognition in diverse disease states, including cancers and
inflammation. The company’s goal is to develop transformative
therapies for diseases with high unmet medical need. GlycoMimetics
is headquartered in Rockville, MD in the BioHealth Capital Region.
Learn more at www.glycomimetics.com.
Forward-Looking Statements
This press release contains forward-looking statements. These
forward-looking statements may include, but are not limited to,
statements regarding the conduct of, and timing for analysis and
presentation of data from, clinical trials; and potential
development and regulatory activities. Actual results may differ
materially from those described in these forward-looking
statements. For a further description of the risks associated with
these statements, as well as other risks facing GlycoMimetics,
please see the risk factors described in the company’s Annual
Report on Form 10-K filed with the U.S. Securities and Exchange
Commission (SEC) on March 27, 2024, the company’s Quarterly Reports
on Form 10-Q filed with the SEC on May 9, 2024 and August 8, 2024,
and other filings GlycoMimetics makes with the SEC from time to
time. Forward-looking statements speak only as of the date of this
release, and GlycoMimetics undertakes no obligation to update or
revise these statements, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241029684934/en/
Investor: Argot Partners Leo Vartorella 212-600-1902
Glycomimetics@argotpartners.com
GlycoMimetics (NASDAQ:GLYC)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
GlycoMimetics (NASDAQ:GLYC)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024